Hs. Friedman et al., Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice, CANC CHEMOT, 48(5), 2001, pp. 413-416
Purpose: This study was conducted to define the activity of irofulven in th
e treatment of a series of xenografts derived from human glioblastoma multi
forme growing subcutaneously and intracranially in athymic nude mice. Metho
ds: Athymic mice bearing subcutaneous or intracranial tumors were treated w
ith irofulven at a 10% lethal dose with responses compared to tumor-bearing
mice treated with drug vehicle. Results: Irofulven was active against all
tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all va
lues statistically significant, P less than or equal to 0.001). Irofulven a
lso produced a statistically significant (P less than or equal to 0.001) in
crease in the median survival Of mice bearing D-456 intracranial xenografts
with a 162% increase in median survival. Conclusions: Irofulven is active
in a spectrum of human glioblastoma multiforme-derived xenografts and evalu
ation in patients with this neoplasm is warranted.